An interventional study of Test Dentifrice and Reference Dentifrice (Aquafresh Cavity Protection) in Dentin Sensitivity and Oral Hygiene, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by HALEON · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Dentin Sensitivity by HALEON — 3 open to participants now, 4 under way, none of them phase 3. Dentin Sensitivity · HALEON.
Among the 21 studies in Dentin Sensitivity by HALEON, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 with no phase, and was the 6th registered.
290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.
Browse Dentin Sensitivity studies →3 of the 21 studies in Dentin Sensitivity by HALEON are open now, in 3 countries. Recruiting first, the newest first:
HALEON · Sites in Canada
Ages 18+ · Healthy volunteers
HALEON · Sites in United States
Ages 18+ · Healthy volunteers
HALEON · Sites in United Kingdom
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 18 Dentin Sensitivity studies recruiting now, 6 (33%) set no upper age limit and 11 (61%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2023.
This study's enrollment of 160 is above the median of 60 across 280 interventional studies indexed under Dentin Sensitivity.
Median enrollment 185 across the 20 interventional studies, 375 across the 1 observational. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
4 of the studies in Dentin Sensitivity by HALEON that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300540HALEONReal-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief | 2026-11 |
| NCT07894796HALEONA Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity | 2027-01 |
| NCT07337109HALEONA Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers | 2027-02 |
| NCT07802886HALEONA Clinical Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Dentin Sensitivity by HALEON, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to investigate the ability of an experimental dentifrice containing 5 percent (%) potassium nitrate (KNO3), 1% alumina and 5% sodium tripolyphosphate (STP), to maintain tooth color and reduce extrinsic dental stain accumulation following peroxide tooth bleaching compared to a regular fluoride dentifrice.
This will be a randomized, single-blind, single-center, controlled, two arm, stratified (clinically diagnosed dentine hypersensitivity [DH] [Yes/No]), parallel group study to evaluate the efficacy of an experimental dentifrice containing 5% KNO3, 1% alumina and 5% STP, to maintain tooth color and reduce the accumulation of extrinsic tooth stain following peroxide tooth bleaching compared to a regular fluoride-containing dentifrice. The study will recruit generally healthy participants who wish to undergo peroxide tooth bleaching. Sufficient participants will be screened to randomize approximately 160 participants to study treatment to ensure approximately 128 evaluable participants complete the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant with generally good oral health that fulfil all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will dose the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 parts per million \[ppm\] fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.
Drug: Test Dentifrice
Participants will dose the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.
Drug: Reference Dentifrice (Aquafresh Cavity Protection)
Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.
Dentifrice containing 1150 ppm fluoride as sodium fluoride.
Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
Time frame: At Week 24 after tooth bleaching
Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
Time frame: At Week 12 after tooth bleaching
Adjusted Mean Total Modified Lobene Stain Index (MLSI) Score at 12 and 24 Weeks After Tooth Bleaching
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean total score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.
Time frame: At Week 12 and Week 24 after tooth bleaching
Adjusted Mean MLSI Score at 12 and 24 Weeks After Tooth Bleaching in Gingival Sites, Interproximal Sites and Body Sites
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. The facial surface of each assessable tooth was divided into individual sites. The gingival site was defined as a crescent-shaped band, approximately 2 millimeters wide, adjacent to the free margin of the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The remainder of the tooth surface was called as body site. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.
Time frame: At Week 12 and Week 24 after tooth bleaching
Adjusted Mean MLSI (Area) Score at 12 and 24 Weeks After Tooth Bleaching
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=area with no stain, 1=Stain covering up to one third of area, 2=Stain covering up to two thirds of area, 3=Stain covering more than two thirds of area. Total score ranged from 0 to 3, where lower score indicated improvement.
Time frame: At Week 12 and Week 24 after tooth bleaching
Adjusted Mean MLSI (Intensity) Score at 12 and 24 Weeks After Tooth Bleaching
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Intensity (I) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=no stain, 1=light intensity stain, 2=moderate intensity stain, 3=heavy intensity stain. Total score ranged from 0 to 3, where lower score indicated improvement.
Time frame: At Week 12 and Week 24 after tooth bleaching
This study was conducted at a single center in the United States.
| Milestone | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Started | 79 | 81 |
| Completed | 75 | 79 |
| Not completed | 4 | 2 |
| Withdrew: Did not meet study criteria | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of a value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
| score on a scale | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Adjusted Mean VITA Shade Score at 24 Weeks After Tooth Bleaching | 12.00 ± 0.355 | 12.06 ± 0.348 |
Tooth color of the facial surfaces of the six anterior maxillary teeth was assessed by a single, trained clinical examiner using the VITA Bleachedguide 3D-MASTER. It consisted of value-ranked ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface was scored visually by the clinical examiner with reference to the Bleachedguide, where lower score indicated improvement.
| score on a scale | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Adjusted Mean VITA Shade Score at 12 Weeks After Tooth Bleaching | 12.08 ± 0.353 | 11.71 ± 0.346 |
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean total score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.
| score on a scale | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Week 12 | 0.69 ± 0.044 | 0.87 ± 0.043 |
| Week 24 | 0.72 ± 0.053 | 1.03 ± 0.052 |
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. The facial surface of each assessable tooth was divided into individual sites. The gingival site was defined as a crescent-shaped band, approximately 2 millimeters wide, adjacent to the free margin of the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The remainder of the tooth surface was called as body site. Area (A) and intensity (I) of extrinsic dental stain were scored separately for each tooth on the scale of 0 to 3 and the mean score was presented, where 0=area with no stain, 1=Stain covering up to one third of area and light intensity stain, 2=Stain covering up to two thirds of area and moderate intensity stain, 3=Stain covering more than two thirds of area and heavy intensity stain. Total MLSI score = Area score multiplied by Intensity score and ranged from 0 to 9, where lower score indicated improvement.
| score on a scale | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Mean Gingival MLSI, Week 12 | 0.02 ± 0.012 | 0.03 ± 0.011 |
| Mean Gingival MLSI, Week 24 | 0.01 ± 0.014 | 0.05 ± 0.014 |
| Mean Interproximal MLSI, Week 12 | 1.37 ± 0.088 | 1.71 ± 0.086 |
| Mean Interproximal MLSI, Week 24 | 1.44 ± 0.105 | 2.04 ± 0.103 |
| Mean Body MLSI, Week 12 | 0.00 ± 0.007 | 0.01 ± 0.007 |
| Mean Body MLSI, Week 24 | 0.00 ± 0.005 | 0.01 ± 0.004 |
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Area (A) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=area with no stain, 1=Stain covering up to one third of area, 2=Stain covering up to two thirds of area, 3=Stain covering more than two thirds of area. Total score ranged from 0 to 3, where lower score indicated improvement.
| score on a scale | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Week 12 | 0.55 ± 0.025 | 0.69 ± 0.024 |
| Week 24 | 0.57 ± 0.027 | 0.74 ± 0.027 |
Extrinsic dental stain was assessed on the facial surfaces of the 6 maxillary anterior teeth using the MLSI. Intensity (I) of extrinsic dental stain was scored separately for each tooth on the scale of 0 to 3, where 0=no stain, 1=light intensity stain, 2=moderate intensity stain, 3=heavy intensity stain. Total score ranged from 0 to 3, where lower score indicated improvement.
| score on a scale | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| Week 12 | 0.46 ± 0.023 | 0.52 ± 0.023 |
| Week 24 | 0.48 ± 0.027 | 0.60 ± 0.026 |
Collected over From signing of informed consent form until 5 days after the last administration of the study product or the last study procedure (up to approximately 195 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Dentifrice | 0/79 (0%) | 1/79 (1.3%) | 39/79 (49.4%) |
| Reference Dentifrice | 0/81 (0%) | 1/81 (1.2%) | 42/81 (51.9%) |
| Event | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 1/79 | 0/81 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/79 | 1/81 |
| Event | Test Dentifrice | Reference Dentifrice |
|---|---|---|
| GINGIVAL PAINGastrointestinal disorders | 15/79 | 21/81 |
| TRAUMATIC ULCERInjury, poisoning and procedural complications | 15/79 | 19/81 |
| HYPERAESTHESIA TEETHGastrointestinal disorders | 9/79 | 15/81 |
| ORAL MUCOSAL EXFOLIATIONGastrointestinal disorders | 7/79 | 2/81 |
| ANGULAR CHEILITISGastrointestinal disorders | 4/79 | 0/81 |
| CHRONIC CHEEK BITINGGastrointestinal disorders | 3/79 | 1/81 |
| GINGIVAL DISCOMFORTGastrointestinal disorders | 3/79 | 0/81 |
| NAUSEAGastrointestinal disorders | 1/79 | 0/81 |
| ORAL DISCOMFORTGastrointestinal disorders | 1/79 | 0/81 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 1/79 | 0/81 |
The Safety population comprised all randomized participants who received at least one dose of the study product.
| Age, Continuous(years) | Test Dentifrice | Reference Dentifrice | Total |
|---|---|---|---|
| Mean | 42.0 ± 11.91 | 37.6 ± 13.04 | 39.8 ± 12.65 |
| Sex: Female, Male(Participants) | Test Dentifrice | Reference Dentifrice | Total |
|---|---|---|---|
| Female | 47 | 45 | 92 |
| Male | 32 | 36 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Test Dentifrice | Reference Dentifrice | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 21 | 43 |
| Not Hispanic or Latino | 57 | 60 | 117 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Test Dentifrice | Reference Dentifrice | Total |
|---|---|---|---|
| African American/African Heritage | 13 | 13 | 26 |
| Asian - East Asian Heritage | 1 | 1 | 2 |
| Asian - Japanese Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 7 | 5 | 12 |
| Native Hawaiian or Other Pacific Islander | 4 | 6 | 10 |
| White - Arabic/North African Heritage | 4 | 3 | 7 |
| White - White/Caucasian/European Heritage | 42 | 41 | 83 |
| Multiple | 7 | 12 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
Ran from Nov 2023 to primary completion in Jul 2024, 7 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 33 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 7 months is above that.
Counting every sponsor, half of 144 studies reached it within 6 months; a quarter within 3 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.